Cannabis Law Report

JULY 25, 2022

million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). The state agency grant funding followed the successful completion of a phase 1 clinical trial in 80 healthy participants.

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

JUNE 19, 2022

For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art. Originally Published At Microdose. However, that does not mean that the path to patents is closed off.

Clinical Trials 52

Clinical Trials Microdosing Data Pharmaceutical 52

Cannabis Law Report

FEBRUARY 9, 2022

But this is the first time Oregonians have been allowed to see some of the nuts and bolts of what some predict could grow into a billion-dollar industry nationally, according to Data Bridge Market Research. Scientists don’t know why this condition occurs, but it isn’t believed to happen with Psilocybe cubensis.

Clinical Trials 52

Clinical Trials Microdosing Safety Conditions 52

CannaMD

OCTOBER 7, 2019

Besides going against all the classic “munchies/stoner” stereotypes, this finding is especially puzzling as cannabis is often used to increase weight gain in patients with medical conditions such as HIV/AIDS and cancer. In 2011, researchers published cross-sectional data from two population-based surveys including over 50,000 respondents.

Marijuana 105

Marijuana Cannabinoids Patients Conditions 105

Cannabis Law Report

JUNE 4, 2021

Rick, and MAPS, have published hundreds of research papers, articles, and reports over the past several decades in addition to participation in dozens of clinical trials and international studies. Dr Rosalind Watts is a clinical psychologist, and the clinical lead of the Psilocybin for Depression trial at Imperial College London.

Research and Development 51

Research and Development Medicine Treatment Pharmaceutical 51